---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-067901"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:54:11.910633+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL

## Summary
- VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.
- Mid dose (2.2mcg) met non-inferiority criteria on seroconversion for 20 of 24 serotypes; dose-dependent responses with little carrier suppression.
- Four VAX-24-unique serotypes met all target criteria at all doses evaluated.
- Company selects mid dose for optimized formulation; plans infant Phase 3 with VAX-24 or VAX-31 pending VAX-31 data (mid-2026).
- Announces VAX-XL, third-generation PCV candidate designed to provide broadest coverage PCV in development.

## SEC filing metadata
- accession: 0001193125-25-067901
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/0001193125-25-067901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-067901
- JSON: https://secwatch.observer/filing/0001193125-25-067901.json
- Plain text: https://secwatch.observer/filing/0001193125-25-067901.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.